Therapeutic Advances in Hematology

Scope & Guideline

Transforming research into impactful therapies.

Introduction

Welcome to the Therapeutic Advances in Hematology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Therapeutic Advances in Hematology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2040-6207
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2010 to 2016, from 2018 to 2024
AbbreviationTHER ADV HEMATOL / Ther. Adv. Hematol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

Therapeutic Advances in Hematology focuses on advancing the understanding and treatment of hematological disorders through innovative research and clinical studies. The journal emphasizes multidisciplinary approaches and encourages contributions that enhance patient care and treatment outcomes.
  1. Hematological Malignancies:
    Research on various hematological malignancies, including acute myeloid leukemia (AML), multiple myeloma, and lymphomas, focusing on novel therapeutic strategies and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Exploration of topics related to transfusion practices, management of bleeding disorders, and advancements in therapies for hemophilia and thrombocytopenia.
  3. Stem Cell Transplantation and Gene Therapy:
    Studies addressing the role of hematopoietic stem cell transplantation (HSCT), including conditioning regimens, donor selection, and the integration of gene therapy in treating hematological diseases.
  4. Patient-Reported Outcomes and Quality of Life:
    Research that evaluates the impact of hematological diseases and their treatments on patients' quality of life, incorporating patient-reported outcomes to inform treatment decisions.
  5. Innovative Treatment Modalities:
    Investigation into new treatment modalities such as CAR-T therapy, bispecific antibodies, and targeted therapies, with a focus on their efficacy and safety in various hematological conditions.
The journal has demonstrated a dynamic evolution in its research themes, with several emerging topics reflecting the latest advancements and priorities in hematology.
  1. Targeted and Personalized Therapies:
    A growing emphasis on targeted therapies, such as B-cell maturation antigen (BCMA) targeting in multiple myeloma, reflects the shift towards personalized medicine tailored to individual genetic profiles.
  2. Immunotherapy Advances:
    The rise of immunotherapeutic strategies, including CAR-T cell therapy and bispecific antibodies, indicates a significant trend towards harnessing the immune system to combat hematological malignancies.
  3. Real-World Evidence and Patient Experience:
    Increased attention to real-world evidence and patient-reported outcomes highlights the importance of understanding treatment impacts from the patient's perspective, influencing clinical practice.
  4. Innovations in Hematopoietic Stem Cell Transplantation:
    Research focusing on advancements in HSCT techniques, including the use of haploidentical donors and novel conditioning regimens, is becoming more prominent as these methods improve patient outcomes.
  5. Management of Rare Hematological Disorders:
    There is an emerging focus on the management and treatment of rare hematological conditions, such as aplastic anemia and paroxysmal nocturnal hemoglobinuria, addressing unmet medical needs.

Declining or Waning

While Therapeutic Advances in Hematology continues to publish impactful research, certain themes appear to be declining in prominence over recent years, potentially reflecting shifts in research focus or advancements in treatment options.
  1. Traditional Chemotherapy Approaches:
    The focus on traditional chemotherapy regimens appears to be waning, as newer targeted therapies and immunotherapies gain prominence in treatment paradigms for hematological malignancies.
  2. Historical Case Reports:
    The journal has seen a decrease in the publication of historical or anecdotal case reports, as the emphasis shifts towards larger, evidence-based studies and clinical trials.
  3. Generalized Treatment Guidelines:
    There is less emphasis on broad treatment guidelines that do not consider individual patient characteristics, as precision medicine and personalized treatment strategies become more prevalent.
  4. Epidemiological Studies:
    Research focused solely on epidemiological data without direct clinical implications seems to be less prioritized, as the journal emphasizes studies that directly impact treatment outcomes and patient care.

Similar Journals

BLOOD

Shaping the Future of Hematological Discovery.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Journal of Blood Medicine

Unlocking Potential: Transforming Knowledge into Practice in Blood Medicine
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

Iraqi Journal of Hematology

Connecting Global Scholars in Blood Science
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

BONE MARROW TRANSPLANTATION

Advancing the Frontiers of Transplantation Science.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

ANNALS OF HEMATOLOGY

Unveiling innovative methodologies for blood health.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

Mediterranean Journal of Hematology and Infectious Diseases

Enhancing understanding through open access to vital research.
Publisher: MATTIOLI 1885ISSN: Frequency: 1 issue/year

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

LEUKEMIA RESEARCH

Unveiling the complexities of hematological science.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0145-2126Frequency: 12 issues/year

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

Transplantation and Cellular Therapy

Exploring the Future of Transplantation and Cellular Therapies.
Publisher: ELSEVIER SCIENCE INCISSN: 2666-6375Frequency: 12 issues/year

Transplantation and Cellular Therapy is a leading journal published by Elsevier Science Inc, dedicated to advancing the fields of transplantation, immunology, cell biology, and molecular medicine. With its ISSN of 2666-6375 and E-ISSN 2666-6367, this journal serves as a vital resource for researchers, practitioners, and students aiming to stay at the forefront of innovative therapies and clinical practices in transplantation. As of 2023, it holds an impressive Q1 ranking in multiple categories, including Cell Biology, Hematology, Immunology and Allergy, Molecular Medicine, and Transplantation, reflecting its high impact and relevance in the scientific community. The journal, operating from its base in the Netherlands, supports Open Access publishing to enhance the dissemination and accessibility of groundbreaking research. Acknowledging the significance of transplantation and cellular therapies in modern medicine, Transplantation and Cellular Therapy is poised to propel future discoveries and developments in these critical domains.

Egyptian Journal of Haematology

Advancing Hematology: Insights from Egypt and Beyond
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Unveiling Innovations in Hematology
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.